Source:
Hindustan
Subject: Health and Governance: Drug Regulation, Antimicrobial Resistance and Public Health|Target exams: UPSC
Key points for Prelims: Antimicrobial resistance (AMR), New Drugs and Clinical Trials Rules, 2019, Drugs Technical Advisory Board (DTAB), Bulk drug wholesale licence (Form 20-BC), Schedule M, One Health approach
Mains syllabus mapping
- General Studies Paper 2: Health: government policies and interventions for health; regulatory mechanisms for drugs and pharmaceuticals
- General Studies Paper 3: Health and public health challenges; antimicrobial resistance; pharmaceutical sector regulation and supply chain

Key facts for one-day exams
- The antimicrobial draft notification was issued on 6 November 2026.
- Proposed Form 19-BC is for bulk drug wholesale licence applications.
- Proposed Form 20-BC is for bulk drug wholesale licences.
- The Drugs Technical Advisory Board held its 93rd meeting on 16 February 2026.
- The revised Schedule M was notified in December 2023.
Why in the news?
The Union health ministry announced proposed amendments to drug rules on Thursday, including bringing antimicrobial products under new-drug testing requirements and introducing a separate wholesale licence for bulk drugs, to strengthen regulatory oversight and address antimicrobial resistance.
The Union health ministry has proposed bringing antimicrobial products under the definition of new drugs, requiring them to undergo clinical trials before manufacturing approval, as part of efforts to tackle antimicrobial resistance. The ministry said in a statement on Thursday that the proposed amendments to the Drugs Rules would also introduce a separate wholesale licence for bulk drug trade. The changes affect manufacturers and wholesalers of antimicrobial products and bulk drugs across the country.
A draft gazette notification issued on 6 November proposes amending Rule 2(1)(w)(v) of the New Drugs and Clinical Trials Rules, 2019 to include antimicrobial products in the new-drug definition. The ministry said the step was taken because antimicrobial resistance is a serious global public-health concern requiring coordinated action, and the G20 New Delhi Leaders’ Declaration had emphasised a One Health approach. Currently, chemical antimicrobial products used in hospitals are not subject to drug manufacturing rules, making it difficult to assess their effectiveness against resistance. Under the proposal, future manufacturing licences will be granted only after products are tested for safety and effectiveness. Existing manufacturing licences will remain valid, and current licence holders will not need to reapply.
Separately, the ministry announced proposed amendments to the Drugs Rules, 1945 to introduce Form 19-BC for applications and Form 20-BC for licences covering wholesale trade in bulk drugs, distinct from the existing licensing arrangement for finished formulations. The Drugs Technical Advisory Board agreed to the proposal at its 93rd meeting on 16 February 2026. The ministry said the change aims to establish a separate licensing system for bulk drug wholesale trade to enable more effective regulatory oversight and improve accountability in the drug supply chain. A further proposal seeks to continue exemptions under the earlier version of Schedule M for medicinal gases, empty gelatin capsules and disinfectant fluids, following stakeholder objections to conditions in the revised Schedule M notified in December 2023.
Key features and how it works
- Defines what counts as a 'new drug' (Rule 2(1)(w)); the draft amendment adds antimicrobials to this definition at sub-clause (v).PIB
- Under the proposal, a two-step licensing route applies: Central Licensing Authority permission first, then the manufacturing licence from the State Licensing Authority.PIB
- The Drugs Controller General of India heads CDSCO and approves clinical trials and new drugs; CDSCO has zonal offices and regulates clinical trials.
- Clinical trials in India must be publicly documented in the Clinical Trials Registry - India, which the Central Drugs Standard Control Organisation has required since 2009 before enrolment.
Related Static GK and comparison
- Central Drugs Standard Control Organisation (CDSCO): responsible for drug approvals, conduct of clinical trials, drug standards and control over the quality of imported drugs.cdsco.gov.in
- Drugs Controller General of India (DCGI): head of CDSCO, responsible for approval of licences for specified categories of drugs, including blood products, IV fluids, vaccines and sera.
- Clinical Trials Registry - India (CTRI): the government's official clinical trial registry, established by the National Institute of Medical Statistics of the Indian Council of Medical Research on 20 July 2007.
- Drugs and Cosmetics Rules, 1945: rules under the Drugs and Cosmetics Act, 1940 that classify drugs into schedules; Schedule Y contains requirements and guidelines for clinical trials.
- Pharmacovigilance Programme of India: tracks reports of harm from the use of drugs.
Achievements
- The draft amendment proposes a central permission step before manufacturers apply for antimicrobial manufacturing licences. The ministry expects this to strengthen central regulatory oversight and help ensure product quality, safety and efficacy.PIB
- The CTRI registration requirement has been reported to help prevent selective reporting of results and duplication of research.
- Trial rules were reformed after the 2013 Supreme Court case Swasthya Adhikar Manch v. Union of India, to make clinical trials more ethical.
Challenges
- In 2015, the government told the Supreme Court that a lack of specific penalties meant it could only halt the HPV vaccine trials and issue warnings.
- Critics say the Indian drug regulator's approval standards are lower than those of the US FDA and the EU's EMA, and that enforcement is weak.
- Registry data quality is a concern, as users register their own trials and the form lacks precision, so errors enter the record.
Way forward
- Finalise the amendment only after the 30-day consultation, with stakeholder objections and suggestions considered by the Central Government.PIB
- Clear penalty provisions for clinical trial violations, which the Drugs and Cosmetics Act currently lacks.
Connected to this news
New Drugs and Clinical Trials Rules, 2019 (proposed amendment to bring antimicrobials under central oversight)
The New Drugs and Clinical Trials Rules, 2019 are India's rules governing new drugs and clinical trials, under which the Health Ministry has proposed (draft of November 2026) to treat antimicrobials as new drugs so that manufacturers need central permission before a state manufacturing licence.
Timeline
19 November 2026
Draft amendment proposed to add antimicrobials to the 'new drug' definition under Rule 2(1)(w)(v), requiring central permission before state manufacturing licences, to curb antimicrobial resistance.
Read the story19 November 2026This story
Story reports the health ministry's proposal to bring antimicrobial products under new-drug testing rules, and to create a separate bulk drug wholesale licence (Forms 19-BC and 20-BC) under the Drugs Rules, 1945.
6 November 2026
Draft amendment G.S.R. 983 (E) issued proposing antimicrobials be included in the 'new drug' definition under Rule 2(1)(w)(v) of the NDCT Rules, 2019.
15 June 2009
CDSCO makes trial registration mandatory, with pre-registration required before enrolment.
20 July 2007
Clinical Trials Registry - India established by the Indian Council of Medical Research.
1945
Drugs and Cosmetics Rules, 1945 framed under the Act.
Proposed bulk drug licensing forms
| Form | Purpose |
|---|---|
| 19-BC | Wholesale licence application |
| 20-BC | Wholesale licence |
Key terms
- Antimicrobial resistance:
- Antimicrobial resistance occurs when microorganisms change so that antimicrobial medicines become less effective against them.
- Antimicrobial product:
- An antimicrobial product destroys microorganisms or inhibits their growth.
- One Health:
- One Health is an approach recognising the interconnected health of people, animals and ecosystems.
- Clinical trial:
- A clinical trial is a research study involving human participants to assess a medical intervention.
- Bulk drug:
- A bulk drug is an active pharmaceutical ingredient used in the manufacture of a medicinal formulation.
Why it matters for exams
Exams: UPSC
Syllabus: Governance: Health regulation and public policy; Science and Technology: Antimicrobial resistance and public health
Common mistake: Examiners may present the antimicrobial amendment as applying retrospectively to existing licences; the proposed amendment concerns future licences, while existing licences remain valid.
Mains practice questions
Question 1(GS-2 | 250 words | 15 marks)
Antimicrobial resistance poses a serious threat to public health, yet chemical antimicrobial products used in hospitals have remained outside drug manufacturing rules. Critically examine the proposal to bring antimicrobial products under the new-drug definition, and discuss its implications for manufacturers and existing licence holders.
Answer outline
- Introduction: Open by noting that antimicrobial resistance is a global One Health concern, and that the draft rule change under the New Drugs and Clinical Trials Rules, 2019 closes a regulatory gap for hospital antimicrobials.
- Body:
- Explain the regulatory gap: chemical antimicrobials used in hospitals were not subject to drug manufacturing rules, making efficacy against resistance hard to assess.
- Benefits: mandatory safety and effectiveness testing before manufacturing approval, alignment with the G20 New Delhi Leaders' Declaration and the One Health approach.
- Concerns: added clinical-trial cost and time for manufacturers, possible effect on availability and pricing, and the need for trained capacity in testing agencies.
- Transitional safeguard: existing manufacturing licences remain valid and holders need not reapply, which limits disruption but raises questions about testing of products already in use.
- Role of stewardship: regulation of manufacture must be paired with rational prescribing and surveillance to tackle resistance effectively.
- Conclusion: Bringing antimicrobials under clinical-trial scrutiny is a necessary step, and its success will depend on a balanced rollout that protects access while strengthening evidence on effectiveness.
Question 2(GS-3 | 150 words | 10 marks)
Separate licensing for bulk drug wholesale trade under Form 19-BC and Form 20-BC is intended to improve oversight of the drug supply chain. Discuss how such a regulatory change can enhance accountability in pharmaceutical supply, and examine the challenges in its implementation.
Answer outline
- Introduction: Introduce the proposal, noting that the Drugs Technical Advisory Board endorsed a distinct licensing system for bulk drugs distinct from finished formulations.
- Body:
- Benefits: a dedicated licence allows regulators to track bulk drug trade separately, improving traceability and accountability in the supply chain.
- Quality assurance: bulk drugs are the raw inputs for formulations, so oversight at the wholesale stage helps curb substandard or spurious inputs.
- Implementation challenges: regulatory capacity at state drug controllers, digitisation of records, and compliance costs for small wholesalers.
- Coordination: harmonising state-level enforcement so the new licence system functions uniformly across the country.
- Conclusion: A separate bulk drug wholesale licence can strengthen supply-chain accountability if paired with adequate enforcement capacity and clear, workable compliance norms.
Stuck? Get it in one tap
Antimicrobial resistance means microorganisms become less responsive to medicines used against them. The government proposes testing antimicrobial products before future manufacturing approval, while protecting existing licences. A separate proposal would create a distinct wholesale licence for bulk drugs.
- Governance: Health regulation and public policy
- Science and Technology: Antimicrobial resistance and public health
Related concepts: Antimicrobial resistance, Antimicrobial product, One Health, Clinical trial
Practice questions
Pick an answer, then read the explanation.
- Q1Hard
Consider the following statements about the proposed antimicrobial product amendment:
- 1. It would include antimicrobial products in the definition of a new drug.
- 2. Existing manufacturing licence holders would have to apply again under the proposal.
- 3. The amendment would apply to licences issued in the future.
Which of the statements given above are correct?
Explanation: Statements 1 and 3 are correct: the proposal adds antimicrobial products to the new-drug definition and applies to future licences. Statement 2 is incorrect because existing licences would remain valid without reapplication.
- Q2Medium
Which proposed form would be used to apply for a bulk drug wholesale licence?
Explanation: Form 19-BC is the proposed application form, while Form 20-BC is the proposed licence form. Forms 19-CB and 20-CB are not the proposed pair.
- Q3Medium
What is the main objective of the proposed separate wholesale licensing system for bulk drugs?
Explanation: Separate bulk drug licensing is intended to strengthen oversight of wholesale trade and accountability in the drug supply chain. Clinical trials, specified Schedule M exemptions and existing antimicrobial licences are addressed by separate proposals.
Frequently asked questions
1. What is proposed for antimicrobial product manufacturing licences?
Antimicrobial products would be included in the new-drug definition and tested before future manufacturing approval.
2. Will existing antimicrobial manufacturing licence holders need to reapply?
Existing licences would remain valid, and their holders would not need to reapply under the proposed amendment.
3. Which forms are proposed for bulk drug wholesale licensing?
Form 19-BC is proposed for applications and Form 20-BC for licences.
4. Which products are covered by the proposed continuation of Schedule M exemptions?
Medicinal gases, empty gelatin capsules and disinfectant fluids are the three specified categories.
All sources
Original19 November 2026 · Read story

